ARCT - NASDAQ
Arcturus Therapeutics Holdings Inc.
$7.60
+0.80%Arcturus Therapeutics Holdings Inc., an RNA medicines company, focuses on the development of vaccines for infectious, and liver and respiratory rare diseases in the United States. The company's development programs comprise LUNAR-OTC development program for ornithine transcarbamylase (OTC) deficiency; and LUNAR-CF program for cystic fibrosis lung disease caused by mutations in cystic fibrosis transmembrane conductance regulator (CFTR) gene, as well as vaccine programs include LUNAR-COV19 and LUNAR-FLU. It has collaboration partnerships with Vinbiocare Biotechnology Joint Stock Company for the manufacture of COVID-19 vaccines; Janssen Pharmaceuticals, Inc. to develop nucleic acid-based therapeutic candidates for the treatment of hepatitis B virus; Ultragenyx Pharmaceutical, Inc. to develop mRNA therapeutic candidates for rare disease targets; CureVac AG to develop mRNA therapeutic and vaccine candidates for various indications; Singapore Economic Development Board and Duke-NUS Medical School to develop LUNAR-COV19 vaccine; and Millennium Pharmaceuticals, Inc. to discover siRNA medicines for the treatment of non-alcoholic steatohepatitis. The company was founded in 2013 and is headquartered in San Diego, California.
At a Glance
Live SnapshotNo Dividend Yield Data
ARCT has not reported any dividend yield values in the available annual periods.
No Dividend Payout Ratio Data
ARCT has not reported any dividend payout ratio values in the available annual periods.
No Net Dividends Paid Data
ARCT has not reported any net dividends paid values in the available annual periods.
Arcturus Therapeutics Holdings Inc. Dividend History
ARCT Dividend Payment History
Total Payments
12
Latest Dividend
$0.0600
Annual Amount
$0.6792
Frequency
Quarterly
| Declaration | Ex-Date | Payment Date | Dividend | Adjusted | Frequency | Growth |
|---|---|---|---|---|---|---|
Dec 27, 2012 | Jan 8, 2013 | Jan 15, 2013 | $0.0080 | $0.0600 | Quarterly | 0.00% |
Dec 27, 2012 | Jan 8, 2013 | Jan 15, 2013 | $0.0080 | $0.0600 | Monthly | 0.00% |
Nov 28, 2012 | Dec 5, 2012 | Dec 15, 2012 | $0.0090 | $0.0600 | Monthly | 0.00% |
Oct 26, 2012 | Nov 6, 2012 | Nov 15, 2012 | $0.0090 | $0.0600 | Monthly | 0.00% |
Sep 27, 2012 | Oct 3, 2012 | Oct 15, 2012 | $0.0090 | $0.0600 | Monthly | 0.00% |
Aug 1, 2012 | Sep 5, 2012 | Sep 15, 2012 | $0.0090 | $0.0600 | Monthly | 0.00% |
Jul 26, 2012 | Aug 6, 2012 | Aug 15, 2012 | $0.0090 | $0.0600 | Monthly | 0.00% |
Jun 27, 2012 | Jul 3, 2012 | Jul 15, 2012 | $0.0090 | $0.0600 | Monthly | 0.00% |
May 29, 2012 | Jun 6, 2012 | Jun 15, 2012 | $0.0090 | $0.0600 | Monthly | 0.00% |
Apr 27, 2012 | May 4, 2012 | May 15, 2012 | $0.0090 | $0.0600 | Monthly | 0.00% |
Mar 14, 2012 | Apr 3, 2012 | Apr 15, 2012 | $0.0090 | $0.0600 | Monthly | +200.00% |
Mar 2, 2012 | Mar 6, 2012 | Mar 15, 2012 | $0.0030 | $0.0200 | Quarterly | - |
Arcturus Therapeutics Holdings Inc. Payout Ratio Analysis
Dividend Sustainability Analysis
Payout Ratio
Conservative payout with excellent safety margin. Company retains significant earnings for growth, acquisitions, or building cash reserves. Dividend is highly sustainable.
FCF Payout Ratio
Negative free cash flow while paying dividends is a major red flag. Company burning cash and cannot sustain dividend without external financing.
Sustainability
Dividend appears unsustainable based on current metrics. High probability of reduction or elimination. Proceed with caution.
Related Guides
Continue your ARCT research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.